Check out our new animated video showcasing ZelosDx's Window into the Brain Technology
The associated annual healthcare cost of neurological disease and trauma is in excess of $1.3 trillion, and is likely to increase due to the rising prevalence of neurological diseases and the aging demographics in the US. There is a lack of methods that can detect the onset of disease before it can destruct the neuronal tissue beyond repair. What is needed are low-cost, objective diagnostic tools that aid in the monitoring of brain health to allow early detection of disease, its progression and outcome.
Our patented WINDOW INTO THE BRAIN technology is currently a research tool that can test human and animal model blood samples across several neurodegenerative disease states
ZelosDx was the first to produce evidence that phagocytic cells carrying brain biomarkers re-enter the blood circulation where they can be easily obtained through a blood sample. These brain biomarkers can be detected in peripheral blood, not only in patients with neurologic disease, but even in healthy donors.
Peripheral blood monocytes provide a novel enriched source of brain-derived biomarkers. Since phagocytes in the blood are short lived, their content of brain specific debris is an indicator of recent damage and may be used as a marker of active neurodegeneration. Hence it may be viewed as a type of brain biopsy providing information about pathological changes in the brain.
ZelosDx has completed three first-generation research assays ready for testing. ZelosDx has termed this approach Window into the Brain(TM), for which it has been granted patent protection in the US, Canada, and Europe.
Copyright © 2024 ZelosDx - All Rights Reserved.